Fredrik Wiklund

Fredrik Wiklund is a Senior Lecturer and Docent at the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet. His research focuses on the genetic epidemiology of prostate and testicular cancer, with particular emphasis on identifying genetic determinants of these diseases. He is actively involved in large international consortia including the PRACTICAL consortium for prostate cancer research and the TECAC consortium for testicular cancer studies.

• PhD in Genetic Epidemiology, Umeå University (2004)
• MSc in Mathematical Statistics, Umeå University (1989)
• Docent (Associate Professor equivalent), Karolinska Institutet (2011)

Dr. Wiklund's research primarily investigates the genetic and epidemiological factors contributing to prostate and testicular cancer development and progression. His work utilizes genomic assessments of large study populations through both genome-wide association studies of common genetic variants and whole exome sequencing of rare coding variants. For prostate cancer, he has a particular focus on determinants of aggressive and lethal disease, leveraging data from over 60,000 prostate cancer patients through the international PRACTICAL consortium. His research on testicular cancer benefits from participation in the TECAC consortium, enabling large-scale genomic assessment of this relatively rare disease. His work bridges population-level epidemiology with molecular genetics to identify risk factors and potential targets for prevention and early detection.

His recent publications demonstrate a strong focus on prostate cancer screening and risk assessment, particularly through the development and validation of the Stockholm3 test in multi-ethnic cohorts. His research spans genetic risk prediction, biomarker discovery, and the clinical application of genomic findings to improve cancer detection and risk stratification. There's a clear emphasis on translating genetic discoveries into clinical practice, with multiple studies examining how genetic information can inform screening strategies and predict disease outcomes across diverse populations.

Dr. Wiklund leads a research group focused on the 'Genetic epidemiology of prostate and testicular cancer' and collaborates extensively with international research teams. His work involves substantial grant funding supporting large-scale genomic studies and clinical validation trials. His research has significant implications for personalized cancer screening approaches and understanding the genetic architecture of urological cancers.